Prognostic markers for CLL - how do they help determine who gets which treatment?
Side effects of idelalisib in CLL and how to manage them
The progress of CLL research: towards targeted therapy
What is the potential of daratumumab in combination therapy for myeloma?
Combinations with FLT3 inhibitors: the way forward for AML treatment